Table 1.
Clinical data on control subjects and WD patients
| Sex | Group | Number | Age mean (range) | CP (mg/dL) mean (±SD) | Copper serum (ug/dL) mean (±SD) | AST(IU/L)a) mean (±SD) | ALT(IU/L)b) mean (±SD) |
|---|---|---|---|---|---|---|---|
| mean (range) | mean (±SD) | mean (±SD) | mean (±SD) | mean (±SD) | |||
| Male | Normal | 6 | 9 (5–12) | 33 (±6.5) | 115 (±17.5) | 35 (±10) | 25 (±10) |
| mWD1c) | 6 | 9 (5–12) | 2.2 (±0.7) | 13.4 (±7.9) | 279 (±228) | 361 (±241) | |
| mWD2 | 6 | 9 (6–12) | 4.1 (±2.0) | 18.8 (±9.9) | 221 (±193) | 260 (±224) | |
| Female | Normal | 7 | 7 (5–12) | 32 (±5) | 105 (±17.5) | 27.5 (±6.3) | 17.5 (±8.8) |
| fWD1d) | 4 | 8 (5–12) | 3.2 (±0.7) | 22.6 (±17.6) | 143 (±84) | 242 (±187) | |
| fWD2 | 4 | 8 (6–10) | 2.7 (±0.4) | 18.4 (±8.6) | 134 (±67) | 218 (±102) |
a)
Aspartate aminotransferase: GOT.
b)
Alanine aminotransferase: GPT.
c)
Male Wilson's disease group.
d)
Female Wilson's disease group.